Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

We are excited to announce the initiation of our HORIZON Study for MZE829, a Phase 2 clinical trial with a novel, potential new medicine that could disrupt current treatment for AKD,” said Harold ...

Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a ...

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.

Maze Therapeutics (MAZE) announced the first patient has been dosed in the company’s Phase 2 clinical trial, the HORIZON Study, of MZE829 in ...

Kidney disease affects millions of Americans, with Black communities facing disproportionately higher risks due to genetic factors, socioeconomic challenges, ...

The NHS has launched a new genetic blood test to improve the safety of kidney donations from people of Black African and ...

Retired NBA All-star revealed that he had kidney cancer and had to get 40% of his kidney removed after going in for ...

Hundreds of potential kidney donors of Black African and Black Caribbean heritage can now get a simple blood test to help reduce the risk of kidney failure. The test is part of national genetic ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the ...

Hundreds of potential kidney donors of Black African and Black Caribbean heritage can now access a simple blood test designed ...

NEW TESTS: The NHS plans to carry out around 160 tests a year to identify people with ‘high-risk’ variants of a gene known as ‘APOL1’, common in people of Black African and Black Caribbean, and the ...